The primary driver of this trend is the introduction and clinical adoption of serological testing for M-type phospholipase A2 receptor (PLA2R) antibodies, a highly specific biomarker for primary membranous nephropathy (MN) [57]. This evidence concerns the gene PLA2R1 and membranous glomerulonephritis.